We are live on ! Find out more
AXSM icon

Axsome Therapeutics

231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 16

75% more call options, than puts

Call options by funds: $106M | Put options by funds: $60.5M

67% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 54

33% more capital invested

Capital invested by funds: $1.97B → $2.61B (+$647M)

17% more funds holding

Funds holding: 197231 (+34)

4.83% more ownership

Funds ownership: 73.31%78.14% (+4.8%)

11% less funds holding in top 10

Funds holding in top 10: 98 (-1)

Holders
231
Holders Change
+34
Holders Change %
+17.26%
% of All Funds
3.63%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
90
Reduced
54
Closed
16
Calls
$106M
Puts
$60.5M
Net Calls
+$45.1M
Net Calls Change
+$22.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Janus Henderson Group
126
Janus Henderson Group
United Kingdom
$1.02M -$1.55K -21 -0.1%
BNP Paribas Financial Markets
127
BNP Paribas Financial Markets
France
$982K -$147K -1,997 -13%
Manulife (Manufacturers Life Insurance)
128
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$968K +$33.3K +451 +3%
ORI
129
Oak Ridge Investments
Illinois
$936K +$961K +13,027 New
Envestnet Asset Management
130
Envestnet Asset Management
Illinois
$929K +$181K +2,457 +23%
Calamos Advisors
131
Calamos Advisors
Illinois
$917K +$941K +12,755 New
AAA
132
Affinity Asset Advisors
New York
$898K +$922K +12,500 New
LCM
133
Legato Capital Management
California
$859K +$363K +4,925 +70%
William Blair & Company
134
William Blair & Company
Illinois
$853K -$122K -1,655 -12%
AQR Capital Management
135
AQR Capital Management
Connecticut
$841K +$213K +2,882 +33%
EAM
136
Erste Asset Management
Austria
$804K
Ensign Peak Advisors
137
Ensign Peak Advisors
Utah
$794K +$81.1K +1,100 +11%
Susquehanna International Group
138
Susquehanna International Group
Pennsylvania
$777K -$1.65M -22,368 -67%
ASRS
139
Arizona State Retirement System
Arizona
$703K +$25.2K +341 +4%
OIA
140
OneDigital Investment Advisors
Kansas
$700K +$2.58K +35 +0.4%
KCM
141
Kennedy Capital Management
Missouri
$700K +$718K +9,738 New
KAS
142
Kestra Advisory Services
Texas
$682K -$23.2K -314 -3%
Teacher Retirement System of Texas
143
Teacher Retirement System of Texas
Texas
$678K -$44K -596 -6%
State Board of Administration of Florida Retirement System
144
State Board of Administration of Florida Retirement System
Florida
$671K -$5.9K -80 -0.8%
PA
145
Profund Advisors
Maryland
$636K -$124K -1,681 -16%
AR
146
Advisory Research
Illinois
$623K +$640K +8,671 New
LPL Financial
147
LPL Financial
California
$618K -$3.69K -50 -0.6%
JF
148
Jump Financial
Illinois
$610K -$3.8M -51,503 -86%
ONB
149
Old National Bancorp
Indiana
$594K
RJA
150
Raymond James & Associates
Florida
$580K +$229K +3,100 +62%

AXSM Hedge Fund Activity: Q2 2023 in Review

231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.

  • 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
  • Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
  • 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
  • The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
  • The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.

Based on aggregated 13F filings for Q2 2023.